- Home
- HRTX vs SLN Comparison
HRTX vs SLN Comparison
Compare HRTX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- SLN
- Stock Information
- Founded
- HRTX 1983
- SLN 1994
- Country
- HRTX United States
- SLN United Kingdom
- Employees
- HRTX N/A
- SLN N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- SLN Health Care
- Exchange
- HRTX Nasdaq
- SLN Nasdaq
- Market Cap
- HRTX 276.1M
- SLN 299.4M
- IPO Year
- HRTX 1987
- SLN N/A
- Fundamental
- Price
- HRTX $1.35
- SLN $4.81
- Analyst Decision
- HRTX Strong Buy
- SLN Buy
- Analyst Count
- HRTX 2
- SLN 5
- Target Price
- HRTX $4.50
- SLN $32.60
- AVG Volume (30 Days)
- HRTX 2.6M
- SLN 61.8K
- Earning Date
- HRTX 08-08-2025
- SLN 08-07-2025
- Dividend Yield
- HRTX N/A
- SLN N/A
- EPS Growth
- HRTX N/A
- SLN N/A
- EPS
- HRTX N/A
- SLN N/A
- Revenue
- HRTX $149,694,000.00
- SLN $27,169,000.00
- Revenue This Year
- HRTX $10.62
- SLN N/A
- Revenue Next Year
- HRTX $12.99
- SLN N/A
- P/E Ratio
- HRTX N/A
- SLN N/A
- Revenue Growth
- HRTX 9.78
- SLN 22.28
- 52 Week Low
- HRTX $1.04
- SLN $1.97
- 52 Week High
- HRTX $2.68
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- SLN 34.88
- Support Level
- HRTX $1.33
- SLN $4.91
- Resistance Level
- HRTX $1.43
- SLN $5.34
- Average True Range (ATR)
- HRTX 0.07
- SLN 0.48
- MACD
- HRTX 0.02
- SLN -0.05
- Stochastic Oscillator
- HRTX 45.45
- SLN 0.71
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.